Screener
R&D at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Agios Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:56 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001439222-26-000118
| (In thousands, except share and per share data) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total revenue | 44,745 | 12,455 | 65,491 | 21,181 |
| Operating expenses: | ||||
| Cost of sales | $2,996 | $1,702 | $4,315 | $2,787 |
| Research and development | 100,754 | 91,940 | 181,902 | 164,683 |
| Selling, general and administrative | 51,547 | 45,869 | 99,851 | 87,396 |
| Total operating expenses | 155,297 | 139,511 | 286,068 | 254,866 |
| Loss from operations | (110,552) | (127,056) | (220,577) | (233,685) |
| Interest income, net | 9,730 | 14,513 | 20,525 | 30,600 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Agios Pharmaceuticals's R&D?
- Agios Pharmaceuticals (AGIO) reported R&D of $100.75M in Q2 2026.
- How has Agios Pharmaceuticals's R&D changed year-over-year?
- Agios Pharmaceuticals's R&D increased by 9.6% year-over-year, from $91.94M to $100.75M.
- What is the long-term trend for Agios Pharmaceuticals's R&D?
- Over 4 years (2021 to 2025), Agios Pharmaceuticals's R&D has grown at a 7.2% compound annual growth rate (CAGR), from $256.97M to $339.54M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Agios Pharmaceuticals's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude